RecruitingPhase 1NCT05865470
Age-dependent Effects of Smoked and Oral Delta-9-THC
Sex- and AGE-dependent Effects of Smoked and Oral Delta-9-THC
Sponsor
University of California, Los Angeles
Enrollment
103 participants
Start Date
Apr 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria7
- Male or non-pregnant female aged 18-65 years according to the below criteria: EMERGING ADULTS: 18-25 years of age (+/- one year) MIDDLE-AGED ADULTS: 35-45 years of age (+/- one year) LATE MIDDLE-AGED ADULTS: 55-65 years of age (+/- one year)
- Report weekly-monthly use of cannabis (with primary mode of use via inhalation) over the past 6 months prior to screening
- Not currently seeking treatment for their cannabis use
- No reported clinically significant adverse effects with cannabis use
- Have a Body Mass Index from 18.5 - 34kg/m2
- Able to perform all study procedures
- FEMALES: Currently practicing an effective form of birth control if pre-menopausal
Exclusion Criteria14
- Meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria for any substance use disorder other than nicotine and mild cannabis use disorder
- Report using other illicit drugs in the prior 4 weeks
- Evidence of severe psychiatric illness (e.g. mood disorder with functional impairment or suicide risk, schizophrenia) or medical condition (i.e., hypertension) judged by the study physician (and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
- Current predominant licit use of medical cannabis
- Current use of prescription or regular use of over the counter medications (with the exception of hormonal contraceptives and hormone replacement therapy). Current use of herbal supplements that may affect study outcomes or interact with study drug (i.e., St Johns wort, kava, L-tryptophan, melatonin)
- If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures
- Current pain
- Pregnancy is exclusionary due to the possible effects of the study medication on fetal development
- History of an allergic reaction or adverse reaction to cannabis is exclusionary.
- Currently enrolled in another research protocol
- Not using a contraceptive method (hormonal or barrier methods)
- The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
- Intolerance to lactose and sesame (ingredients in the oral THC preparation)
- Insensitivity to the Cold Pressor Test
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCannabis
smoked cannabis
DRUGDronabinol
Oral delta-9-THC
DRUGSmoked Placebo
Placebo Cannabis
DRUGOral Placebo
Oral Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05865470
Related Trials
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055118 locations
Testing the Pain Clinical Practice Guideline
NCT0585899611 locations
Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study
NCT075810802 locations
Clinical and Scientific Assessment of Pain and Painful Disorders
NCT027070291 location
Options for Pain Management Using Nonpharmacological Strategies
NCT055637921 location